Prior studies have indicated that brain cancer occurs with more frequency in Northern Europe, North America and Australia with Russia, India, the United States, China and Brazil having the highest brain tumor mortality rates. There has also been a significant increase in global brain and central nervous system cancer rates over the past few decades, with the number of cases surging by 94.35% from 1990 to 2019.
A new study has now revealed that brain tumors are the fifth most common type of cancer in the nation. These tumors often occur as a result of a growth of abnormal cells in the brain. The deadly cancer ranked fifth after female breast cancer, prostate cancer, colorectal cancer and melanoma.
This study shows that even though brain tumors are relatively rare and affect less than 1% of the population, they are relatively common among Americans. The researchers behind this study tapped into a Central Brain Tumor Registry of the United States and studied patient data from 2000–2019. They obtained data on the incidence of nonbrain-tumor cancers among American patients from the database; they also gathered additional data from the Surveillance, Epidemiology, and End Results (SEER) program.
After examining the data, the researchers estimated that as of Dec. 31, 2019, there were 1,323,121 people living in the United States who had been diagnosed with a primary brain tumor. In addition, 85.3% of the Americans who received a primary brain tumor diagnosis had nonmalignant brain tumors. Additional data indicated that 43.5% of all brain tumor patients were aged 65 years and older while 40.0% were 40 to 64 years old, 14.3% were adolescents and young adults aged 15 to 39 years old, and 2.1% were children younger than 15 years of age.
The researchers found that brain tumors were the fifth most common type of cancer among adults aged 40–64. Brain tumors were the most common cancer type in young adults and adolescents with 35% of the cases being malignant tumors. Brain tumors were the second most prevalent type of cancer in children after leukemia and 65.4% of the brain cancer cases in this age group were malignant. On the other hand, brain tumors were the seventh most common cancer in adults aged 65 and older with 94.1% of the cases being nonmalignant.
The researchers also discovered that women had a higher brain cancer prevalence rate than males at a female-to-male ratio of 1.68. However, malignant tumors tended to be common in men of all age groups despite having a low prevalence for brain tumors.
Companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) that are engaged in developing treatments for various forms of brain cancer have a huge role to play in identifying formulations which may help the U.S. and other countries fight back against this huge brain cancer burden.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
